EMERGENT STRATEGIES

Lobbying for GENBIOPRO, INC. · Generic Pharmaceutical Manufacturer

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Nevada · House · Senate · posted Apr 20, 2026

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.